The Cambrian Biopharma-backed cancer treatment developer floated above its range in an offering on the Nasdaq Global Market.
US-based oncology treatment developer Sensei Biotherapeutics has raised $133m in an upsized initial public offering (IPO) on the Nasdaq Global Market that provided an exit for medical research group Cambrian Biopharma. The company issued 7 million shares priced at $19 each, above the $16 to $18 range it had set for the offering, valuing it…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
